Skip to main content
main-content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Complementary and Alternative Medicine 1/2018

Long-term effects of Garcinia cambogia/Glucomannan on weight loss in people with obesity, PLIN4, FTO and Trp64Arg polymorphisms

Zeitschrift:
BMC Complementary and Alternative Medicine > Ausgabe 1/2018
Autoren:
Andrea Maia-Landim, Juan M. Ramírez, Carolina Lancho, María S. Poblador, José L. Lancho
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12906-018-2099-7) contains supplementary material, which is available to authorized users.

Abstract

Background

Overweight and obesity are considered major health problems that contribute to increase mortality and quality of life. Both conditions have a high prevalence across the world reaching epidemic numbers. Our aim was to evaluate the effects of the administration of Garcinia cambogia (GC) and Glucomannan (GNN) on long-term weight loss in people with overweight or obesity.

Methods

Prospective, not-randomized controlled intervention trial was conducted. We treated 214 subjects with overweight or obesity with GC and GNN (500 mg twice a day, each) for 6 months evaluating weight, fat mass, visceral fat, basal metabolic rate, and lipid and glucose blood profiles comparing them with basal values. Some patients were carriers of polymorphisms PLIN4 -11482G > A-, fat mass and obesity-associated (FTO) -rs9939609 A/T- and β-adrenergic receptor 3 (ADRB3) -Trp64Arg.

Results

Treatment produced weight loss, reducing fat mass, visceral fat, lipid and blood glucose profiles while increasing basal metabolic rate. Results were independent of sex, age or suffering from hypertension, diabetes mellitus type 2 or dyslipidemia and were attenuated in carriers of PLIN4, FTO, Trp64Arg polymorphisms.

Conclusions

Administration of GC and GNN reduce weight and improve lipid and glucose blood profiles in people with overweight or obesity, although the presence of polymorphisms PLIN4, FTO and ADRB3 might hinder in some degree these effects. ISRCTN78807585, 19 September 2017, retrospective study.
Zusatzmaterial
Additional file 1: TREND Statement Checklist. (PDF 1254 kb)
12906_2018_2099_MOESM1_ESM.pdf
Additional file 2: TRENDS flowchart. (JPEG 965 kb)
12906_2018_2099_MOESM2_ESM.jpg
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Complementary and Alternative Medicine 1/2018 Zur Ausgabe